FOR IMMEDIATE RELEASE

Sitges, Spain, January 30, 2020 - Today over 1,200 European researchers, clinicians, nurses, patients, regulators, and industry are gathering in Sitges for the 2nd European CAR T Cell Meeting, organized by the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT). This 3-day meeting is compiled with speakers that will share first-hand knowledge and experience, including the pioneers in the field, on this new and promising treatment of blood cancers.

From EMA approval to successful implementation
The recent approval of the first CAR T Cell treatments in Europe presents a great opportunity to fight hematological malignancies, but also poses serious challenges given the peculiar nature of the treatment. For a successful implementation of this promising therapy whole health systems need to learn how to select the right treatments, handle specific toxicities, organize treatment units and cope with the increasing costs connected with CAR T therapy. This meeting will build on the knowledge and experience shared at the 1st EHA-EBMT European CAR T Cell Meeting in February 2019 in Paris, and is aimed at providing an overview of CAR T Cell developments in Europe.

Crossing borders and medical fields
The meeting includes a comprehensive outlook on the current research efforts in Europe, the USA and China to increase CAR T Cell therapies efficacy and targets. The program links the clinical aspects with input from basic researchers, patients as well as industry representatives. In addition, special tracks have been development by and for nurses and data managers, who play an important role in the implementation of the new therapy.

For the full scientific program click this link.

About EHA
The European Hematology Association (EHA) promotes excellence in patient care, research and education in hematology.

EHA envisions a cure for all blood disorders by connecting hematologists worldwide, supporting their career development, harmonizing hematology education and advocating the interests of hematology and hematologists in the European arena.

With more than 5,000 members from 100+countries, and 12,000+ participants in its Annual Congress, EHA is Europe’s largest professional organization supporting both clinicians and scientists around the globe in their efforts to towards a cure for all blood diseases.
About EBMT

The European Society for Blood and Marrow Transplantation (EBMT) is a not-for-profit medical and scientific organisation established in 1974. It is dedicated to fighting life-threatening blood cancers and diseases and improving patients’ lives.

The EBMT Members - more than 4,500 physicians, nurses, scientists and other healthcare professionals - participate in a unique collaborative network of peers involved in haematopoietic stem cell transplantation (HSCT) and cellular therapy research.

The EBMT patient Registry was established in the early 1970’s. It is the only data source of its kind in Europe. The data are submitted continuously by more than 550 centres, including from outside Europe. The Registry holds data on more than 650,000 HSCT procedures including details on disease, transplant type, donor type and stem cell source. It contains data on patients that have undergone HSCT and also on patients receiving immunosuppressive therapies or other cell therapies. The Registry also offers the possibility to enter donors’ follow-up data, which is crucial to ensure maximum donor safety. The Registry underpins extensive European research that translates into changes in clinical practice and improvements in patient outcome and care.

For further information about the EBMT, please visit [www.ebmt.org](http://www.ebmt.org) and follow us on Twitter: @TheEBMT

Contact

For more information on this meeting, please contact [communication@ehaweb.org](mailto:communication@ehaweb.org) or [communications@ebmt.org](mailto:communications@ebmt.org).